1. Home
  2. QCLS vs LSTA Comparison

QCLS vs LSTA Comparison

Compare QCLS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QCLS

Q/C Technologies Inc.

SELL

Current Price

$4.03

Market Cap

31.1M

Sector

Health Care

ML Signal

SELL

Logo Lisata Therapeutics Inc.

LSTA

Lisata Therapeutics Inc.

HOLD

Current Price

$3.54

Market Cap

28.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QCLS
LSTA
Founded
2014
1980
Country
United States
United States
Employees
2
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Misc Health and Biotechnology Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.1M
28.9M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
QCLS
LSTA
Price
$4.03
$3.54
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
396.5K
98.6K
Earning Date
04-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.42
EPS
N/A
N/A
Revenue
N/A
$35,283,868.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
56.90
52 Week Low
$2.50
$1.81
52 Week High
$8.17
$5.07

Technical Indicators

Market Signals
Indicator
QCLS
LSTA
Relative Strength Index (RSI) 51.86 53.53
Support Level $3.86 $3.06
Resistance Level $4.66 $3.67
Average True Range (ATR) 0.28 0.17
MACD -0.00 0.02
Stochastic Oscillator 53.68 29.73

Price Performance

Historical Comparison
QCLS
LSTA

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

Share on Social Networks: